Shigeoka, T., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Horikawa, T., Tanaka, T., Irie, S., Motonaga, R., Hamanoue, N., Tanabe, M., et al
Fragmentation with staphylococcal protease results in GIP1-3 and GIP4-42, fragmentation with enterokinase in GIP1-16 and GIP17-42
As the host of the Dr
And in short that came out a few years after that STEP 1 trial what we did for the very first time is take individuals with obesity and pre-existing cardiovascular disease, like a prior stroke, prior heart attack, or peripheral arterial disease, called PAD, and they're on maximal therapy for their cardiovascular disease or stroke, and then randomized them on top of that to either semaglutide or placebo
It works by mimicking glucagon-like peptide-1 (GLP-1), a hormone naturally produced in the gut, which regulates appetite, promotes satiety, and stabilizes blood sugar levels
Retrieved from GLP-1 Receptor Agonists